EMA - Alzheimer Europe (AE) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 January 2026, 14:00 (CET) to 20 January 2026, 15:00 (CET)

Submitted by Anonymous (not verified) on 16 March 2026 - 8:56

EMA - Alzheimer Europe (AE) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 January 2026, 14:00 (CET) to 20 January 2026, 15:00 (CET)

Opinion/decision on a Paediatric investigation plan (PIP): Vidaza, azacitidine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology, PIP number: P/0217/2015

Submitted by Anonymous (not verified) on 16 March 2026 - 8:41

Opinion/decision on a Paediatric investigation plan (PIP): Vidaza, azacitidine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology, PIP number: P/0217/2015

Human medicines European public assessment report (EPAR): Pradaxa, dabigatran etexilate, Date of authorisation: 17/03/2008, Revision: 46, Status: Authorised

Submitted by Anonymous (not verified) on 13 March 2026 - 15:40

Human medicines European public assessment report (EPAR): Pradaxa, dabigatran etexilate, Date of authorisation: 17/03/2008, Revision: 46, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness